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Allergy-provoking histamine keeps itself 
under control, according to a study on page 
387. Schneider and colleagues show
that basophil precursor cells pump released 
histamine back into themselves. Once 
inside, the histamine shuts off its own 
production and that of allergy-promoting 
T helper (Th) 2 cytokines.
Basophils and mast cells are the primary 
histamine producers of the immune system. 
In mature cells, histamine is stored in 
intracellular granules and is rapidly released 
when the cells are stimulated. Once released, 
histamine triggers acute allergy symptoms 
by binding to its receptors on vascular 
endothelial cells and bronchial smooth 
muscle cells. Histamine can also be produced 
by nongranular cells, including macrophages 
and dendritic cells, which secrete the 
molecule immediately after synthesis.
This group previously described a 
population of low-granule basophil 
 
Neutrophil detox
 
On page 353, Han and colleagues describe a novel chemical
inhibitor that shuts down the production of inflammation-
induced oxidants by neutrophils, but does not compromise
the ability of the cell to attack invading pathogens. This selective
neutrophil disarmament may provide a way to limit the
tissue-damaging side effects of neutrophil activation without
crippling anti-microbial defenses—a feat presumed by many
to be impossible.
Neutrophils are among the immune system’s earliest
responders against invading pathogens. If these cells are missing
or unable to function properly, life-threatening bacterial and
fungal infections ensue. Neutrophil assault on invading
pathogens is mediated in part by the release of reactive oxy-
gen intermediates (ROIs) that damage microbes. But the
benefits of this protection come at a cost. The same ROIs
that help kill microbes contribute to the tissue damage that
is often associated with prolonged inflammation.
As a result of this double-edged sword, a major challenge
of anti-inflammatory therapy is to block the damaging side
effects of neutrophils without crippling their anti-microbial
functions. Han and colleagues have now found a chemical
inhibitor that meets this tall order. The inhibitor blocked
ROI production by neutrophils in response to the inflammatory
cytokine tumor necrosis factor (TNF), but not in response to
bacterial pathogens or a phorbol ester. Other neutrophil func-
tions, including bacterial killing, migration, and degranulation
Neucalcin-1 treatment 
(bottom) prevents TNF-
induced calcium flux (yellow 
and orange) in neutrophils.
 
precursor cells in the bone marrow that 
produce histamine and Th2 cytokines. This 
cell population increases in size during 
worm infections and may help resolve 
infection by promoting a protective Th2 
response. The authors had noted that these 
cells could take up histamine from the 
external environment, but neither the 
mechanism nor the consequences of this 
uptake were understood. Schneider et al. 
now show that the uptake of histamine by 
these cells triggers a negative feedback 
loop that inhibits additional histamine 
synthesis and the production of allergy-
promoting cytokines.
Histamine transport was dependent 
on a cation transporter protein (organic 
cation transporter 3, or OCT3), which was 
known to transport histamine in brain 
cells but had never been identified on 
basophils. The authors speculate the 
reverse histamine transport may help 
limit the severity of allergic responses. 
They are now testing this idea by 
assessing allergic responses in OCT3-
deficient mice. 
Histamine pumped back into basophil precursor 
cells inhibits further synthesis of histamine.
 
Histamine self control
 
were also unaffected by the inhib-
itor. This suggests that it is indeed
possible to dissect neutrophil acti-
vation, a biological response that,
according to senior author Carl
Nathan, “was always presumed to
be monolithic.”
The inhibitor—dubbed neu-
calcin-1—worked by blocking
the build-up of intracellular cal-
cium that is normally triggered
by TNF. The defective calcium
flux prevented the activation of
soluble adenylyl cyclase, which
was required for the activation
of a guanosine triphosphatase
that associates with the ROI-
producing enzyme complex on
the plasma membrane. Although
many details of this pathway re-
main to be unraveled, these data
identify a completely new branch
of TNF signaling and demonstrate the possibility of fine-
tuning neutrophil inhibition without blocking TNF, which
is required for the activation of other cell types and for
protection against many bacterial infections. 
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Debating DAP12
 
Mice that lack the adaptor protein DAP12 
defy deadly bacterial infections, according 
to Turnbull and colleagues on page
363. DAP12-deficient mice developed a 
muted inflammatory response, allowing 
the immune system to clear the bacteria 
without triggering septic shock.
DAP12 is a transmembrane adaptor 
protein that is associated with an array of 
DAP12-deficient mice (dotted 
line) are resistant to a lethal endo-
toxin challenge.
 
activating receptors on the surface of immune, brain, and bone cells. DAP12 is 
required for the development of bone-resorbing osteoclasts, but its role in immune 
cells is less clear. Some studies have suggested that DAP12-dependent signals 
amplify cellular activation and inflammatory cytokine production in response to 
invading microbes, but others argue that DAP12 signaling inhibits these functions.
Turnbull et al. now weigh in on this debate by showing that mice lacking 
DAP12 can fend off a systemic bacterial infection without producing shock-
inducing amounts of inflammatory cytokines such as tumor necrosis factor, 
suggesting that DAP12 signaling normally amplifies inflammation. These data 
are consistent with their previous studies in which blocking the DAP12-associated 
receptor TREM-1, which is expressed on granulocytes and monocytes, 
protected mice against septic shock.
The resistance of the DAP12-deficient mice to bacterial infections is 
consistent with the situation in humans. Humans lacking DAP12 develop a 
lethal bone wasting and neurodegenerative disease, but do not seem to be 
more susceptible to infections. Thus far, the benefit of expressing DAP12 on 
immune cells that respond to bacterial infections remains a mystery. 
 
TIM-2 tones down Th2
 
The TIM (T cell immunoglobulin mucin) proteins are emerging as critical
regulators of T helper (Th) cell responses and as potential susceptibility factors
for the development of allergic and autoimmune diseases. On page 437,
Chakravarti and colleagues add to the developing TIM story by showing that
TIM-2 is preferentially expressed on differentiated Th2 cells and inhibits
their expansion and function. These molecules, according to senior author
Vijay Kuchroo, are not only critical modulators of the CD4
 
 
 
 Th cell
response, but are the first reliable markers of differentiated Th cell subsets.
The 
 
TIM
 
 genes were originally identified as residents of a chromo-
somal locus that conferred susceptibility to asthma. Since then, this group
has shown that TIM3 is expressed exclusively on polarized Th1 cells and
dampens their activation. They now show an analogous function for
TIM-2 on Th2 cells. Blocking TIM-2 increased the production of Th2
cytokines and protected mice against Th1-driven experimental auto-
immune encephalomyelitis, suggesting that TIM-2 normally inhibits
excessive activation of Th2 cells.
Although the signals in T cells that drive the expression of TIM2 and
TIM3 are not known, their exclusive expression on polarized Th cells
(not simply activated T cells) suggests that TIM2 and TIM3 expression
may be driven by Th2- and Th1-specific transcription factors, respec-
tively. The structure of the TIM molecules, which most closely resembles
the adhesion molecule MAdCAM, suggests that these proteins may also
affect lymphocyte trafficking. 
 
Bone cells unite
 
Bone-resorbing osteoclasts can’t pull together
in the absence of dendritic cell–specific trans-
membrane protein (DC-STAMP), according
to new data from Yagi and colleagues (page
345). Without this receptor, osteoclast
precursor cells cannot fuse with one another.
The failure to fuse cripples the bone resorbing
function of the cells, causing osteopetrosis
(increased bone mass).
DC-STAMP is a seven-transmembrane–
spanning receptor that was originally isolated
from dendritic cells (DCs). The ligand for
DC-STAMP and its function on DCs are un-
known, but this receptor was recently found
on osteoclasts and shown to be required for
these cells to develop from their macrophage
precursors.
Yagi and colleagues now refine these
data by showing that multinucleated osteo-
clasts were completely absent in the bones of
mice lacking DC-STAMP, although osteoclast
development was intact. The DC-STAMP–
deficient mice suffered from mild osteopetro-
sis, as mononucleated osteoclasts can still resorb
bone. Whether DC-STAMP triggers fusion
directly or triggers the expression of other
fusion-inducing receptors remains to be
determined.
The absence of DC-STAMP also in-
hibited the formation of foreign body giant
cells—products of macrophage fusion that
dispose of foreign bodies in tissues. Although
the mechanism is not yet known, DC-
STAMP may function as a fusion coreceptor
in a fashion analogous to the fusion of HIV
with target cells, which depends on seven-
transmembrane–spanning chemokine receptors
(see commentary from Vignery, on page
337). 
Fusion of preosteoclasts to generate multinucleated 
osteoclasts is defective in the absence of DC-STAMP 
(right).
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